Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Carcinoma, Ductal, Breast Clear all
Completed No phase listed Observational

X-Ray Mammography Standard of Care Protocol

NCT01052740
View directory record Official record
Conditions
Breast Cancer, Invasive Carcinoma, In Situ Carcinoma, Fibrocystic Changes, Atypical Ductal Hyperplasia
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 11:46 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

NCT02620852
View directory record Official record
Conditions
Breast Cancer Screening, Breast Carcinoma in Situ, Breast Cancer
Interventions
Complete a health questionnaire, Provide a saliva sample for genetic testing, Screening advice based on a comprehensive risk assessment, Screening advice based on a basic risk assessment
Other · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
30 Years to 74 Years · Female only
Enrollment
100,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
11
States / cities
Birmingham, Alabama • Irvine, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jul 23, 2026, 11:46 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

NCT05919108
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer, Anatomic Stage III Breast Cancer, Invasive Breast Lobular Carcinoma
Interventions
Endocrine Therapy, Biopsy of breast, Neratinib, Biospecimen Collection, Mammogram, Magnetic Resonance Imaging, Breast Surgery, Ultrasound
Procedure · Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
5
States / cities
Atlanta, Georgia • Pittsburgh, Pennsylvania • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Jul 23, 2026, 11:46 PM EDT
Completed Not applicable Interventional Results available

Study to Assess Perfusion and Patient Satisfaction in Nipple-Areola Mastectomy With Immediate Reconstruction

NCT01969448
View directory record Official record
Conditions
Ductal Carcinoma in Situ - Category, Breast Cancer, Prophylactic Mastectomy
Interventions
Inframammary Fold Incision or Lateral Radial Incision, Lateral Radial Incision, Inframammary Fold Incision, Laser-assisted fluorescence angiography, Indocyanine Green
Procedure · Device · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Jul 23, 2026, 11:46 PM EDT
Recruiting Not applicable Interventional

Neoadjuvant Breast Cancer Time Restricted Eating

NCT05327608
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Ductal Carcinoma in Situ, HER2 Negative Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Carcinoma
Interventions
Time Restricted Eating
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Jul 23, 2026, 11:46 PM EDT
Active, not recruiting Not applicable Interventional

Accelerated Partial Breast Irradiation Following Lumpectomy for Breast Cancer

NCT00185744
View directory record Official record
Conditions
Breast Cancer, Carcinoma, Ductal
Interventions
Intra-Operative Radiotherapy (IORT), Lumpectomy, Whole Breast Radiotherapy, Intracavitary Brachytherapy, Accelerated External Beam 3-D Conformal Radiotherapy, Stereotactic APBI
Radiation · Procedure
Lead sponsor
Stanford University
Other
Eligibility
40 Years and older · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2029
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 23, 2026, 11:46 PM EDT
Completed Not applicable Interventional Results available

MarginProbe, a Device for Intraoperative Assessment of Margin Status in Breast Conservation Surgery

NCT00749931
View directory record Official record
Conditions
Breast Cancer
Interventions
MarginProbe, Lumpectomy
Device · Procedure
Lead sponsor
Dune Medical Devices
Industry
Eligibility
18 Years to 90 Years · Female only
Enrollment
664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
18
States / cities
Costa Mesa, California • Los Angeles, California • Newport Beach, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Jul 23, 2026, 11:46 PM EDT
Terminated Phase 3 Interventional

Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer

NCT00267553
View directory record Official record
Conditions
Breast Neoplasms, Neoplasms, Hormone-Dependent
Interventions
Atamestane, toremifene, letrozole
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
Greenbrae, California • Saint Joseph, Michigan • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2007 · Synced Jul 23, 2026, 11:46 PM EDT
Terminated Phase 3 Interventional

The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

NCT00097344
View directory record Official record
Conditions
Breast Neoplasms, Neoplasms, Hormone-Dependent
Interventions
Atamestane, Toremifene, Letrozole, Aromatase inhibition, Estrogen receptor blocker, Hormone therapy, Endocrine therapy, Antiestrogen therapy
Drug · Procedure
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
842 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
49
States / cities
Mobile, Alabama • Tuscon, Arizona • Hot Springs, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2007 · Synced Jul 23, 2026, 11:46 PM EDT
Not listed Phase 1Phase 2 Interventional

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NCT04913337
View directory record Official record
Conditions
Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Breast Cancer, Ovarian Cancer, Cervical Cancer, Endocervical Cancer, Colorectal Cancer, Esophageal Cancer
Interventions
NGM707, NGM707 plus pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
20
States / cities
Los Angeles, California • Newport Beach, California • Santa Monica, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Jul 23, 2026, 11:46 PM EDT
Not listed Not applicable Interventional

Intraoperative Boost Radiotherapy With Electrons (IOERT) Followed By Hypofractionated Whole-Breast Irradiation (WBRT)

NCT01295723
View directory record Official record
Conditions
Invasive Lobular and Ductal Carcinoma
Interventions
Hypofractionated Whole Breast Radiation Therapy, Intraoperative Electron Radiation Therapy
Radiation
Lead sponsor
St. Joseph Hospital of Orange
Other
Eligibility
40 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Jul 23, 2026, 11:46 PM EDT
Completed Phase 2 Interventional Results available

Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer

NCT02636582
View directory record Official record
Conditions
Breast Ductal Carcinoma In Situ
Interventions
Laboratory Biomarker Analysis, Nelipepimut-S Plus GM-CSF Vaccine, Sargramostim, Surgical Procedure
Other · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Jul 23, 2026, 11:46 PM EDT
Completed No phase listed Observational

Assessing the Impact of the Microbiome on Breast Cancer Radiotherapy Toxicity

NCT04245150
View directory record Official record
Conditions
DCIS, Invasive Breast Cancer
Interventions
Stool sample, Skin Swab Sample
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Timeline
2019 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 23, 2026, 11:46 PM EDT
Completed Phase 3 Interventional

Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ

NCT00003857
View directory record Official record
Conditions
Breast Cancer
Interventions
tamoxifen citrate, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
26 Years to 120 Years · Female only
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2022
U.S. locations
305
States / cities
Mobile, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 235 more
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Jul 23, 2026, 11:46 PM EDT
Terminated Phase 2 Interventional Results available

St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer

NCT00110136
View directory record Official record
Conditions
Breast Cancer, Hot Flashes
Interventions
St. John's Wort
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
19
States / cities
Newark, Delaware • Washington D.C., District of Columbia • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Jul 23, 2026, 11:46 PM EDT
Withdrawn No phase listed Observational

Ductal Lavage in Assessing Women With Early Breast Cancer or at High Risk of Developing Breast Cancer and Who Are Eligible For Tamoxifen Therapy

NCT00083044
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 64 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
2
States / cities
Birmingham, Alabama • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 24, 2012 · Synced Jul 23, 2026, 11:46 PM EDT
Terminated Phase 2 Interventional Results available

A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)

NCT00183963
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Tamoxifen, Fulvestrant
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Jul 23, 2026, 11:46 PM EDT
Terminated No phase listed Observational

Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women

NCT05755269
View directory record Official record
Conditions
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Lobular Carcinoma In Situ
Interventions
Biospecimen Collection, Genotyping, Survey Administration
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 75 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 23, 2026, 11:46 PM EDT
Active, not recruiting Phase 2 Interventional

Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study

NCT05545150
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Bilateral Breast Carcinoma, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8
Interventions
Intraoperative Imaging, Lumpectomy
Procedure · Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Lexington, Kentucky • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Jul 23, 2026, 11:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer

NCT01219075
View directory record Official record
Conditions
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
Interventions
soy isoflavones, placebo, questionnaire administration, magnetic resonance imaging, biopsy, immunohistochemistry staining method, laboratory biomarker analysis, mammography
Dietary Supplement · Other · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
30 Years to 75 Years · Female only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Jul 23, 2026, 11:46 PM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery

NCT01082211
View directory record Official record
Conditions
Breast Cancer
Interventions
3D-Conformal External Beam
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
57
States / cities
Peoria, Arizona • Burbank, California • Aurora, Colorado + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Jul 23, 2026, 11:46 PM EDT
Completed Phase 2 Interventional Results available

Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer

NCT01869764
View directory record Official record
Conditions
Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Male Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
omega-3 fatty acid, placebo, laboratory biomarker analysis
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Jul 23, 2026, 11:46 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

NCT06943521
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Prostate Cancer, Urothelial Carcinoma, Neuroendocrine Tumor (NET), Neuroendocrine Carcinoma (NEC), Soft Tissue Sarcoma, Nuclear Protein in Testis (NUT) Carcinoma
Interventions
MT-4561
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Grand Rapids, Michigan • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Jul 23, 2026, 11:46 PM EDT
Completed Not applicable Interventional Results available

Partial Breast Irradiation (PBI) for Selected Patients With Early Invasive or Non-Invasive Breast Cancer

NCT00694577
View directory record Official record
Conditions
Ductal Breast Cancer
Interventions
Partial Breast Irradiation using 32 Gy / 8 fractions, Partial Breast Irradiation using 36 Gy / 9 fractions, Partial Breast Irradiation using 40 Gy /10 fractions
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Jul 23, 2026, 11:46 PM EDT